Switch theme
Sign up to access all valuation multiples
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
2007
761
LTM Revenue $317M
LTM EBITDA $46.4M
$212M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Castle Biosciences has a last 12-month revenue (LTM) of $317M and a last 12-month EBITDA of $46.4M.
In the most recent fiscal year, Castle Biosciences achieved revenue of $332M and an EBITDA of $38.1M.
Castle Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Castle Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $317M | XXX | $332M | XXX | XXX | XXX |
| Gross Profit | $249M | XXX | $272M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 82% | XXX | XXX | XXX |
| EBITDA | $46.4M | XXX | $38.1M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 11% | XXX | XXX | XXX |
| EBIT | -$30.2M | XXX | $8.7M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | -$20.6M | XXX | $18.2M | XXX | XXX | XXX |
| Net Margin | -7% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Castle Biosciences's stock price is $16.
Castle Biosciences has current market cap of $461M, and EV of $212M.
See Castle Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $212M | $461M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Castle Biosciences has market cap of $461M and EV of $212M.
Castle Biosciences's trades at 0.6x EV/Revenue multiple, and 5.6x EV/EBITDA.
Equity research analysts estimate Castle Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Castle Biosciences has a P/E ratio of -22.3x.
See valuation multiples for Castle Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $461M | XXX | $461M | XXX | XXX | XXX |
| EV (current) | $212M | XXX | $212M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 4.6x | XXX | 5.6x | XXX | XXX | XXX |
| EV/EBIT | -7.0x | XXX | 24.4x | XXX | XXX | XXX |
| EV/Gross Profit | 0.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -22.3x | XXX | 25.3x | XXX | XXX | XXX |
| EV/FCF | 11.1x | XXX | 5.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCastle Biosciences's last 12 month revenue growth is -7%
Castle Biosciences's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Castle Biosciences's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Castle Biosciences's rule of X is -2% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Castle Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -7% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | -84% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -27% | XXX | 5% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -2% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 79% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Castle Biosciences acquired XXX companies to date.
Last acquisition by Castle Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Castle Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Castle Biosciences founded? | Castle Biosciences was founded in 2007. |
| Where is Castle Biosciences headquartered? | Castle Biosciences is headquartered in United States of America. |
| How many employees does Castle Biosciences have? | As of today, Castle Biosciences has 761 employees. |
| Who is the CEO of Castle Biosciences? | Castle Biosciences's CEO is Mr. Derek J. Maetzold. |
| Is Castle Biosciences publicy listed? | Yes, Castle Biosciences is a public company listed on NAS. |
| What is the stock symbol of Castle Biosciences? | Castle Biosciences trades under CSTL ticker. |
| When did Castle Biosciences go public? | Castle Biosciences went public in 2019. |
| Who are competitors of Castle Biosciences? | Similar companies to Castle Biosciences include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Castle Biosciences? | Castle Biosciences's current market cap is $461M |
| What is the current revenue of Castle Biosciences? | Castle Biosciences's last 12 months revenue is $317M. |
| What is the current revenue growth of Castle Biosciences? | Castle Biosciences revenue growth (NTM/LTM) is -7%. |
| What is the current EV/Revenue multiple of Castle Biosciences? | Current revenue multiple of Castle Biosciences is 0.7x. |
| Is Castle Biosciences profitable? | Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Castle Biosciences? | Castle Biosciences's last 12 months EBITDA is $46.4M. |
| What is Castle Biosciences's EBITDA margin? | Castle Biosciences's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Castle Biosciences? | Current EBITDA multiple of Castle Biosciences is 4.6x. |
| What is the current FCF of Castle Biosciences? | Castle Biosciences's last 12 months FCF is $19.1M. |
| What is Castle Biosciences's FCF margin? | Castle Biosciences's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of Castle Biosciences? | Current FCF multiple of Castle Biosciences is 11.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
